PharmaFocus Today – Page 23 – media

Tianguangshi’s new drug marketing authorization application for MIL62 for the treatment of primary membranous nephropathy has been accepted

　　According to a report from People’s Finance on October 12th, Beijing Yizhuang WeChat account, Beijing Tianguangshi Biotechnology Co., Ltd. (hereinafter referred to as “Tianguangshi”), a company in Beijing Economic and Technological Development Zone (Beijing Yizhuang), recently announced that its independently developed innovative third-generation CD20 antibody MIL62 for the treatment of primary membranous nephropathy (PMN) has been accepted by the National Medical Products Administration. It is reported that this is the world’s first drug to be approved for the treatment of PMN. Its breakthrough not only provides a better treatment option for PMN, but also demonstrates China’s innovative drug development.Leading advantages in drug research and development and industrialization. https://finance.eastmoney.com/a/202510123531477277.html
- Source: drugdu
- 107
- October 13, 2025
Its subsidiary’s core product, TROP2 ADC Lukangsatuzumab, has been approved by the National Medical Products Administration for a third indication.

　　Kelun PharmaceuticalThe announcement stated that Kelun Biotech’s controlled subsidiary, sac-TMT, an antibody-drug conjugate (ADC) targeting human trophoblast cell surface antigen 2 (TROP2), has been approved by the National Medical Products Administration for a third indication: the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation-positive disease who have progressed after treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). sac-TMT is the first and only ADC in the world to date to demonstrate a significant overall survival (OS) benefit compared to platinum-based doublet chemotherapy and has been approved for advanced NSCLC that has progressed after prior TKI therapy (2L). https://finance.eastmoney.com/a/202510123531499855.html
- Source: drugdu
- 89
- October 13, 2025
Fentanyl-stimulant overdose deaths surge among older adults

Overdose deaths in adults age 65 and older from fentanyl mixed with stimulants, such as cocaine and methamphetamines, have surged 9,000% in the past eight years, matching rates found among younger adults, according to research presented at the ANESTHESIOLOGY® 2025 annual meeting. The study is among the first to use Centers for Disease Control and Prevention (CDC) data to show that older adults, a group often overlooked in overdose research, are part of the broader rise in fentanyl-stimulant overdose deaths. Adults 65 years and older are especially vulnerable to overdoses because many live with chronic health conditions, take several medications and process drugs more slowly due to age. The opioid epidemic has unfolded in four waves, each characterized by a different type of opioid driving the increase in overdose deaths: prescription opioids in the 1990s; heroin starting in 2010; fentanyl starting in 2013; and a mix of fentanyl and stimulants ...
- Source: drugdu
- 65
- October 13, 2025
Study reveals distinct links between depression subtypes and metabolic diseases

It is known that depression is linked to increased incidence of metabolic diseases; now scientists have discovered that different types of depression are linked to different cardiometabolic diseases. This work is presented at the ECNP Congress in Amsterdam. Over seven years, researchers tracked 5,794 adults, enrolled in the Netherlands Epidemiology of Obesity (NEO) Study, all of whom were free of diabetes and cardiovascular disease at the study’s start. At the start of the study each participant completed a comprehensive questionnaire to assess depressive symptoms. The team identified two distinct depressive profiles: one typified by “melancholic” symptoms (such as early morning awakening and reduced appetite), and another by “atypical/energy-related” symptoms (such as fatigue, increased sleep, and increased appetite). Around 8% of the participants developed a cardiometabolic condition during the follow-up period, but the type of condition they developed depended on the type of depression they had. Those with atypical/energy-related” symptoms were ...
- Source: drugdu
- 71
- October 13, 2025
Sanofi achieves a major victory in Phase II clinical trials, challenging its dominance as the “number one nuclear medicine company”!

Sanofi announced that its targeted alpha nuclide therapy AlphaMedix achieved all primary efficacy endpoints in the Phase II clinical trial ALPHAMEDIX-02, demonstrating significant clinically meaningful efficacy in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This achievement not only further confirms the potential of targeted α therapy to provide precise treatment for GEP-NETs, but also marks Sanofi’s challenge to Novartis, the “No. 1 nuclear medicine company.” 01 New Force Alpha Nuclide AlphaMedix is a targeted alpha therapy based on lead-212. It consists of a peptide complex that binds to somatostatin receptors and is coupled to a radionuclide. It serves as an in vivo generator of alpha particles. Due to their high energy and short range, alpha particles can precisely kill cancer cells while minimizing damage to surrounding healthy tissue, presenting potential therapeutic advantages. AlphaMedix wasn’t developed independently by Sanofi, but rather a key move in rapidly expanding its nuclear medicine portfolio ...
- Source: drugdu
- 128
- October 11, 2025
Paclitaxel for Injection Obtains Marketing Authorization in Multiple Countries

　　Shanghai Securities News China SecuritiesNetxun Huiyu Pharmaceutical announced on the evening of the 9th that its subsidiary Seacross Pharma (Europe) Ltd. recently received marketing authorization for the company’s product paclitaxel for injection (albumin-bound) approved and issued by the Netherlands Medicines Evaluation Committee, the Irish Health Products Regulatory Authority, the Finnish Medicines Agency, and the Swedish Medicines Agency. 　　Paclitaxel (albumin-bound) for injection is primarily indicated as monotherapy for the treatment of adult patients with metastatic breast cancer whose disease has not improved after first-line treatment of metastatic disease and for whom standard anthracycline-containing regimens are not appropriate; in combination with gemcitabine, it is indicated for the first treatment of adult patients with metastatic pancreatic adenocarcinoma; and in combination with carboplatin, it is indicated for the initial treatment of adult patients with non-small cell lung cancer who are not suitable for potentially curative surgery or radiotherapy. 　　Huiyu Pharmaceuticals stated that following its ...
- Source: drugdu
- 101
- October 11, 2025
Sinovac’s quadrivalent influenza vaccine has been approved to cover people aged 6 months and above

　　Shanghai Securities News China SecuritiesNet News (Reporter Zhang Xue) The reporter learned from Sinovac Holdings on October 10 that recently, Beijing Sinovac BiotechQuadrivalent influenza virusThe National Medical Products Administration (NMPA) has approved an expanded age range for the Sinovac quadrivalent influenza vaccine, expanding its coverage to include individuals aged 6-35 months, in addition to those aged 3 years and above. With this expanded age range, the Sinovac quadrivalent influenza vaccine now covers all ages 6 months and older and is currently in use in nearly 20 countries and regions worldwide. 　　Infants and young children aged 6-35 months are at high risk for influenza- related complications. Flu vaccination is the most effective and economical way to prevent influenza and reduce the risk of complications. Furthermore, families are a key venue for influenza transmission. Studies have shown that 26% of influenza infections can be attributed to transmission within the family, and the ...
- Source: drugdu
- 146
- October 11, 2025
No more chemotherapy after gastric cancer surgery? Henlius’s successful clinical trial of Hans-like therapy is the world’s first

　　This newspaper (Reporter Jin Wanxia) reported on October 9 that Shanghai Fuhong Hanlin Biotech Co., Ltd. (hereinafter referred to as ” Fuhong Hanlin “) announced that the company’s Phase III clinical study of its self-developed innovative PD-1 inhibitor Hanseluzumab (slulizumab) combined with chemotherapy for neoadjuvant/monoadjuvant treatment of gastric cancer has met the pre-set superiority criteria and the treatment regimen has a good safety profile. This is the world’s first treatment regimen for gastric cancer in the perioperative (preoperative/postoperative) period to replace postoperative adjuvant chemotherapy with a single immunotherapy agent, achieving a major breakthrough in this field. 　　In light of these data, Henlius intends to advance its marketing authorization application for this indication. Dr. Zhu Jun, Executive Director and CEO of Henlius, stated, “Gastrointestinal cancer is a core area of focus for Henlius. We will actively promote the translation of our research findings to benefit patients as soon as possible, and ...
- Source: drugdu
- 93
- October 11, 2025
Multimodal nanocarriers offer targeted solutions for tumor treatment

Cancer remains a leading cause of global morbidity and mortality. Traditional therapies like chemotherapy and radiotherapy are often limited by their lack of specificity, leading to systemic toxicity and the emergence of drug resistance. Nanoparticles, with dimensions ranging from 1 to 100 nm, offer a sophisticated solution. Their unique physicochemical properties allow them to navigate biological barriers and can be engineered for active targeting (e.g., using ligands for overexpressed cancer cell receptors) or passive targeting (exploiting the Enhanced Permeability and Retention effect of tumor vasculature). The cellular uptake of these nanocarriers is a critical process, primarily occurring through various endocytic pathways such as clathrin-mediated, caveolin-mediated, and macropinocytosis, followed by crucial intracellular steps like endosomal or lysosomal escape to ensure the therapeutic cargo reaches its target intact. Nanocarriers in drug-delivery systems for cancer treatment A diverse arsenal of nanocarriers has been developed, each with distinct advantages and limitations. Liposomes, spherical phospholipid ...
- Source: drugdu
- 79
- October 11, 2025
Drug Combo Effective Against Advanced Prostate Cancer

By Dennis Thompson HealthDay ReporterFRIDAY, Oct. 10, 2025 (HealthDay News) — A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom advance, according to findings published Oct. 7 in the journal Nature Medicine. The combination was even more effective among men with genetic mutations driving their prostate cancer, researchers noted. “Although current standard treatments are very effective for the majority of patients with advanced prostate cancer, a small but very significant proportion of patients have limited benefit,” said lead researcher Dr. Gerhardt Attard, chair of medical oncology with the University College London Cancer Institute. “By combining with niraparib we can delay the cancer returning and hopefully significantly prolonging life expectancy,” he said in a news release. Niraparib is a “maintenance” drug approved to keep certain types of cancer ...
- Source: drugdu
- 76
- October 11, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.